Insider Transactions in Q1 2021 at Mersana Therapeutics, Inc. (MRSN)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2021
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
SELL
Open market or private sale
|
Direct |
8,203
-6.12%
|
$139,451
$17.5 P/Share
|
|
Mar 22
2021
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,203
+5.77%
|
$32,812
$4.84 P/Share
|
|
Feb 22
2021
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
SELL
Open market or private sale
|
Direct |
8,203
-6.12%
|
$164,060
$20.01 P/Share
|
|
Feb 22
2021
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,203
+5.77%
|
$32,812
$4.84 P/Share
|
|
Jan 20
2021
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
SELL
Open market or private sale
|
Direct |
8,203
-6.12%
|
$172,263
$21.54 P/Share
|
|
Jan 20
2021
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,203
+5.77%
|
$32,812
$4.84 P/Share
|
|
Jan 19
2021
|
Ashish Mandelia VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
545
-100.0%
|
$11,445
$21.28 P/Share
|
|
Jan 15
2021
|
Ashish Mandelia VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
289
-34.65%
|
$6,069
$21.09 P/Share
|
|
Jan 15
2021
|
Ashish Mandelia VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
834
+50.0%
|
-
|
|
Jan 15
2021
|
Anna Protopapas Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,198
-2.26%
|
$109,158
$21.09 P/Share
|
|
Jan 15
2021
|
Anna Protopapas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,709
+7.15%
|
-
|
|
Jan 15
2021
|
Brian De Schuytner SVP, COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,162
-15.32%
|
$24,402
$21.09 P/Share
|
|
Jan 15
2021
|
Brian De Schuytner SVP, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,959
+34.29%
|
-
|
|
Jan 15
2021
|
Michael J. Kaufman Chief Manufacturing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,957
-29.35%
|
$41,097
$21.09 P/Share
|
|
Jan 15
2021
|
Michael J. Kaufman Chief Manufacturing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+50.0%
|
-
|
|
Jan 15
2021
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,324
-6.88%
|
$48,804
$21.09 P/Share
|
|
Jan 15
2021
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,917
+18.99%
|
-
|
|
Jan 12
2021
|
Andrew A. F. Hack |
BUY
Open market or private purchase
|
Indirect |
75,000
+1.99%
|
$1,350,000
$18.16 P/Share
|
|
Jan 11
2021
|
Andrew A. F. Hack |
BUY
Open market or private purchase
|
Indirect |
75,000
+2.03%
|
$1,350,000
$18.52 P/Share
|
|
Jan 08
2021
|
Andrew A. F. Hack |
BUY
Open market or private purchase
|
Indirect |
100,000
+2.74%
|
$1,800,000
$18.39 P/Share
|
|
Jan 04
2021
|
Ashish Mandelia VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
247
-100.0%
|
$6,422
$26.76 P/Share
|